About

Publication thumbnail: Herpes zoster in Patients with Inflammatory Arthritides or Ulcerative Colitis Treated with Tofacitinib, Baricitinib or Upadacitinib: A Systematic Review of Clinical Trials and Real-world Studies

Herpes zoster in Patients with Inflammatory Arthritides or Ulcerative Colitis Treated with Tofacitinib, Baricitinib or Upadacitinib: A Systematic Review of Clinical Trials and Real-world Studies

Publication thumbnail: The Effect of Guselkumab on Inhibiting Radiographic Progression in Patients with Active Psoriatic Arthritis: Study Protocol for APEX, a Phase 3b, Multicenter, Randomized, Double‑blind, Placebo‑controlled Trial

The Effect of Guselkumab on Inhibiting Radiographic Progression in Patients with Active Psoriatic Arthritis: Study Protocol for APEX, a Phase 3b, Multicenter, Randomized, Double‑blind, Placebo‑controlled Trial

Publication thumbnail: Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomised Controlled Trials

Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomised Controlled Trials

Publication thumbnail: Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network

Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network

Publication thumbnail: Achilles Enthesitis on Physical Examination Leads to Worse Outcomes After 2 Years of Follow up in Patients with Ankylosing Spondylitis From REGISPONSER-AS Registry

Achilles Enthesitis on Physical Examination Leads to Worse Outcomes After 2 Years of Follow up in Patients with Ankylosing Spondylitis From REGISPONSER-AS Registry

Publication thumbnail: Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-responder and Secondary Non-responder of Prior TNF Inhibitor in Ankylosing Spondylitis

Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-responder and Secondary Non-responder of Prior TNF Inhibitor in Ankylosing Spondylitis

Discussing AxSpA: Episode 5

Discussing Rheumatology: January 2023

Author Interview: Kevin Winthrop

Discussing PsA: Episode 5

Publication thumbnail: Bimekizumab in Patients with Psoriatic Arthritis, Naive To Biologic Treatment: A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial (BE OPTIMAL)

Bimekizumab in Patients with Psoriatic Arthritis, Naive To Biologic Treatment: A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial (BE OPTIMAL)

Publication thumbnail: Bimekizumab In Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor-Α Inhibitors: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Bimekizumab In Patients with Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor-Α Inhibitors: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Publication thumbnail: Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label  Extension Study

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Publication thumbnail: Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

Publication thumbnail: Emerging Therapies for the Treatment of Spondyloarthritides with Focus on Axial Spondyloarthritis

Emerging Therapies for the Treatment of Spondyloarthritides with Focus on Axial Spondyloarthritis

Author Interview: Rebecca Haberman

Publication thumbnail: Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate

Publication thumbnail: Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis

Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis

Publication thumbnail: Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Publication thumbnail: Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

Publication thumbnail: Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Publication thumbnail: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Publication thumbnail: Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Publication thumbnail: Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a Randomized Phase IIb Study of Abatacept in Psoriatic Arthritis

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a Randomized Phase IIb Study of Abatacept in Psoriatic Arthritis

Publication thumbnail: Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States

Real-world Treatment Patterns and Use of Adjunctive Pain and Anti-inflammatory Medications Among Patients with Psoriatic Arthritis Treated With IL-17A Inhibitors In The United States

Publication thumbnail: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Publication thumbnail: Deucravacitinib in Moderate-to-severe Psoriasis

Deucravacitinib in Moderate-to-severe Psoriasis

Publication thumbnail: Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Publication thumbnail: Efficacy and Safety of Non-Pharmacological and Non-Biological Interventions: A Systematic Literature Review Informing the 2022 Update of the ASAS/EULAR Recommendations for the Management of AxSpA

Efficacy and Safety of Non-Pharmacological and Non-Biological Interventions: A Systematic Literature Review Informing the 2022 Update of the ASAS/EULAR Recommendations for the Management of AxSpA

Publication thumbnail: ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update

ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update

Publication thumbnail: Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis

Publication thumbnail: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX:  A Post Hoc Analysis of the FINCH 1 Study

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study